Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26.Read More
Neovasc (NASDAQ:NVCN) provided an update on the clinical experience with its Tiara transcatheter mitral valve, sending the shares up 50% to $2.14 at midday Dec 6.Read More
Closely-held CorWave has completed a $17.1-million Series B financing with existing shareholders, including Sofinnova Partners, Bpifrance and Seventure, and two new investors: Novo Seeds, which led the round, and Ysios Capital.
CorWave has developed a disruptive pumping technology that mimics the native heart flow pattern and could overcome limitations of rotary pump left ventricular assist devices (LVAD) for patients who have reached end-stage heart failure. The company was incorporated by MD Start, a European medtech incubator, in 2011 and raised a Series A financing in 2013.Read More
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Capricor Therapeutics (NASDAQ:CAPR) with a “buy” rating and $13 price target. The stock closed at $4.27 on Tuesday.
Capricor has developed three regenerative medicine platforms. They are cardiosphere-derived cells (CDC) for the treatment of heart failure and cardiac regeneration; natriuretic peptides for heart failure; and exosomes for yet-to-be disclosed indications.Read More